Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

22 janv. 2015 08h00 HE | Source: Kite Pharma, Inc.

Kite Pharma Announces Expanded Agreement with Tel Aviv Sourasky Medical Center and Pioneering Researcher Professor Zelig Eshhar to Develop Novel Chimeric Antigen Receptor (CAR) Approaches for Cancer Immunotherapy

SANTA MONICA, Calif., Jan. 22, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
19 janv. 2015 15h00 HE | Source: Kite Pharma, Inc.

Kite Pharma Announces Presentations Highlighting Cancer Immunotherapy T Cell Manufacturing Process

SANTA MONICA, Calif., Jan. 19, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
09 janv. 2015 08h00 HE | Source: Kite Pharma, Inc.

Kite Pharma Expands Senior Management Team With Appointment of Claudine Prowse, Ph.D., as SVP, Corporate Communications and Investor Relations

SANTA MONICA, Calif., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
08 janv. 2015 17h14 HE | Source: Kite Pharma, Inc.

Kite Pharma Announces Addition of Scott N. Bernstein as Vice President of Intellectual Property Law

SANTA MONICA, Calif., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
07 janv. 2015 13h00 HE | Source: Kite Pharma, Inc.

Kite Pharma Announces Exclusive License With the National Institutes of Health for T Cell Receptor (TCR)-Based Products to Treat HPV-Associated Cancers

SANTA MONICA, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
07 janv. 2015 08h00 HE | Source: Kite Pharma, Inc.

Kite Pharma to Present at the 33rd Annual J.P. Morgan Healthcare Conference

SANTA MONICA, Calif., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
06 janv. 2015 08h00 HE | Source: Kite Pharma, Inc.

Kite Pharma Granted Orphan Drug Designation in the European Union for KTE-C19, Kite's Lead Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy

SANTA MONICA, Calif., Jan. 6, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
30 déc. 2014 08h30 HE | Source: Kite Pharma, Inc.

Kite Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

SANTA MONICA, Calif., Dec. 30, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
22 déc. 2014 12h40 HE | Source: Kite Pharma, Inc.

Kite Pharma Submits Investigational New Drug Application for Phase 1/2 Trial of KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, for the Treatment of Refractory Aggressive Non-Hodgkin Lymphoma

SANTA MONICA, Calif., Dec. 22, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...
16 déc. 2014 08h00 HE | Source: Kite Pharma, Inc.

Kite Pharma Added to the NASDAQ Biotechnology Index

SANTA MONICA, Calif., Dec. 16, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE),a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy...

Page précédente

Page suivante